EmeraMedEmeraMed Ltd is a biotechnology firm developing the lipophilic, blood-brain-barrier passing metal chelator and antioxidant Irminix® (Code: NBMI, INN: Emeramide).

Mercury poisoningThe Company has Orphan Drug Designation for the Prevention and Treatment of Mercury toxicity in the EU and USA. Phase 1 and Phase 2a clinical studies have been performed. Phase 2b is in planning.

COPDA Phase 2a clinical trial is ongoing for the treatment of COPD and finished by November 2017.

Other conditionsPreclinical studies ongoing for other indications.

Expanded access/Early access: A SwissMedic (Switzerland) and FDA (USA) have approved Irminix® for Named Patient/Compassionate use. For more information – please click above.

Subscribe To Our Mailing List: (* indicates required)

Email Format